Dr. Michael Burke is an Associate Professor at Children’s Wisconsin in the Division of Hematology/Oncology. He is Director of the Pediatric Leukemia & Lymphoma Program at Children's and Co-Director of the Developmental Therapeutics Program where he oversees all early phase clinical trials (Phase I and II studies) at Children's. He has developed both early phase and upfront clinical trials in acute leukemia that have opened locally here at Children's Wisconsin as well as nationally and internationally through consortiums such as the Children’s Oncology Group (COG) and the Therapeutic Advances in Childhood Leukemia & Lymphoma Consortium (TACL). Dr. Burke is the principal investigator of a Phase I trial for relapsed ALL and a phase I trial in relapsed AML both through the TACL consortium as well as study chair for the upfront COG trial for children with High-Risk and Very High-Risk B-cell ALL.

Dr. Burke’s research interests have focused on reporting clinical outcomes for both children and adults with high-risk leukemia for which he has over 30 publications as well as the development of early phase clinical trials investigating novel agents and/or combination therapies for relapsed/refractory acute leukemia. He did his pediatric residency at the Medical College of Virginia /Virginia Commonwealth University in Richmond Virginia and pediatric fellowship training in hematology-oncology at Northwestern University Lurie Children’s Hospital in Chicago, Illinois.